LONDON (Reuters) - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market. AstraZeneca has flagged Lynparza, or olaparib, as a potential $2-billion-a-year seller. The formal approval from the European Commission had been expected after the European Medicines Agency gave the drug a green light in October but the news is still significant given earlier uncertainties. ...
via Health News Headlines - Yahoo News http://ift.tt/1sIpTpU
No comments:
Post a Comment